患者登记系统及其在药械监管中的应用研究

doi:10.11669/cpj.2021.09.012

摘要
图/表
参考文献(50)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的回顾患者登记系统的发展过程,总结分析其关键要素,阐述患者登记研究的设计步骤及其在监管决策中的应用,为推动患者登记在我国监管决策中的应用提出合理建议。方法采用国内外文献研究法,从上市前药械临床评价和上市后药械监测两个方面,明晰患者登记应用时需考虑的关键问题。结果患者登记可应用于支持监管决策,例如,评估疾病自然史;确定试验或治疗的临床效果,成本效果或相对有效性;衡量或监测与使用特定产品相关的安全性和有效性。结论某些情况下,将患者登记作为证据开发工具可以填补临床试验结果与实际临床实践之间的空白,但其在我国的应用仍存在短板,因此,加强数据收集和分析的基础设施建设,完善患者登记研究沟通和审评机制至关重要。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王雪
	杨悦

关键词 ：患者登记, 真实世界, 药械监管

Abstract：OBJECTIVE To review the development process of the patient registries, summarize and analyze its key elements and explain the design steps of patient registration research and its application in regulatory decision-making, put forward reasonable suggestions for promoting the application of patient registries in Chinese regulatory decision-making. METHODS Based on domestic and foreign literature research method, from the two aspects of pre-marketing drug device clinical evaluation and post-marketing monitoring, this paper clarified the key issues that need to be considered in patient registries and application. RESULTS Patient registration can be used to support regulatory decision-making, for example, to evaluate the natural history of a disease; determine the clinical effect, cost-effectiveness, or relative effectiveness of a trial or treatment; measure or monitor the safety and effectiveness of specific products. CONCLUSION In some cases, the use of patient registration as an evidence development tool can fill the gap between clinical trial results and actual clinical practice, but its application in China still has shortcomings. Therefore, it is necessary to strengthen the construction of data collection and analysis infrastructure and improve the communication and review mechanism for patient registries studies is crucial.

Key words： patient registry real world drugs and medical devices regulation

收稿日期: 2020-08-25

PACS:

R951

通讯作者: * 杨悦,女,教授研究方向:药事法规与药品政策 Tel: (010)63096644 E-mail:yyue315@vip.126.com

作者简介: 王雪,女,硕士研究生研究方向:药事管理

引用本文:

王雪, 杨悦. 患者登记系统及其在药械监管中的应用研究[J]. 中国药学杂志, 2021, 56(9): 762-769. WANG Xue, YANG Yue. Patient Registry System and Its Application of Supporting Drugs and Medical Devices Regulation. Chinese Pharmaceutical Journal, 2021, 56(9): 762-769.

链接本文:

http://journal11.magtechjournal.com/Jwk_zgyxzz/CN/10.11669/cpj.2021.09.012 或 http://journal11.magtechjournal.com/Jwk_zgyxzz/CN/Y2021/V56/I9/762

[1]	ERNEST S, CHRISTOPHER P C, PATRICK W S. Should real-world evidence be incorporated into regulatory approvals?[J]. Expert Opin Drug Saf, 2018,17(12):1155-1159.
[2]	SHERMAN R E, ANDERSON S A, DAL PAN G J, et al. Real-world evidence-what is it and what can it tell us？[J]. N Engl J Med, 2016, 375(23):2293-2297.
[3]	TROTTER J P. Patient registries: a new gold standard for "real world" research[J]. Ochsner J, 2002,4(4):211-214.
[4]	FDA.Framework for FDA's Real-World Evidence Program[EB/OL]. (2018-12)[2019-07-07]. https://www.fda.gov/media/120060/download.
[5]	GLIKLICH R E,DREYER N A, LEAVY M B. Registries for Evaluating Patient Outcomes: A User's Guide [R]. 3rd ed. Rockville (MD): Agency for Healthcare Research and Quality (US), 2014.
[6]	YUE L Q. Leveraging real-world evidence derived from patient registries for premarket medical device regulatory decision-making[J]. Stat Biopharm Res, 2018, 10(2):98-103.
[7]	Richard Gliklich, Good Practice for Patient Registries.[EB/OL]. (2008-09-09) [2020-06-20]. https://www.powershow.com/view2b/478c80-NWQ2Z/Good_Practice_for_Patient_Registries_AHRQ_Annual_Meeting_Bethesda_MD_September_9_2008_Speaker_Richard_Gliklich _MD_Principal_Investigator_Outcome_DEcIDE_Center_President_Outcome_Cambridge_MA_powerpoint_ppt_presentation.
[8]	NATIONAL CANCER INSTITUTE SEER Training Modules.Brief History of Cancer Registration,[EB/OL]. [2020-06-20]. https://training.seer.cancer.gov/registration/registry/history/.
[9]	IRGENS L M, BJERKEDAL T. Epidemiology of leprosy in norway: the history of The National Leprosy Registry of Norway from 1856 until today[J]. Int J Epidemiol, 1973, 2(1):81-89.
[10]	PARKIN D M. The evolution of the population-based cancer registry[J]. Nat Revi Cancer,2006,6(8):603-612.
[11]	World Health Organization. National cancer control programmes: policies and managerial guidelines: executive summary.[EB/OL]. (2002) [2020-06-20]. https://apps.who.int/iris/handle/10665/42527.
[12]	GOLDBERG J, GELFAND H M, LEVY P S. Registry evaluation methods: a review and case study[J]. Epidemiol Rev,1980,2(1):210-220.
[13]	Centers for Disease Control and Prevention. [EB/OL]. [2020-06-11]. https://www.cdc.gov/cancer/npcr/about.htm.
[14]	Health Catalyst. Precise Patient Registries: The Foundation for Clinical Research & Population Health Management. [EB/OL]. (2014-11-12) [2020-06-20]. https://www.healthcatalyst.com/webinar/precise-patient-registries-the-foundation-for-clinical-research-population-health-management/.
[15]	FDA. Guidance for Industry Establishing Pregnancy Exposure Registries. [EB/OL]. (2002-08) [2020-07-20]. https://www.fda.gov/media/75607/download.
[16]	FDA. Guidance for Industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment. [EB/OL] (2005-03) [2020-07-20]. https://www.fda.gov/media/71546/download.
[17]	Agency for Healthcare Research and Quality. Effective Health Care Program.[EB/OL]. [2020-06-20]. https://effectivehealthcare.ahrq.gov/about/former/.
[18]	BOUVY J C, BLAKE K, SLATTERY J, et al. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013[J]. Pharmacoepidemiol Drug Saf,2017,26(2):1442-1450.
[19]	IRDiRC. EMA initiative for the collection of high-quality data on medicines through patient registries.[EB/OL]. (2016-11-12) [2020-06-11]. https://irdirc.org/ema-initiative-to-the-collection-of-high-quality-data-on-medicines-through-patient-registries/.
[20]	EMA. Initiative for patient registries. [EB/OL]. (2015-09-15) [2020-06-20]. https://www.ema.europa.eu/en/documents/other/initiative-patient-registries-strategy-pilot-phase_en.pdf.
[21]	National Institute on Deafness and Other Communication Disorders. National Organization for Rare Disorders (NORD) [EB/OL]. (2020-06-23) [2020-07-20]. https://www. nidcd. nih. gov/directory/national-organization-rare-disorders-nord.
[22]	National Institute on Deafness and Other Communication Disorders. National Organization for Rare Disorders (NORD). [EB/OL] (2020-06-23) [2020-07-20]. https://www. nidcd. nih. gov/directory/national-organization-rare-disorders-nord.
[23]	EMA. Discussion paper:Use of patient disease registries for regulatory purposes-methodological and operational considerations. [EB/OL]. [2020-06-20]https://www.ema.europa.eu/en/documents/other/discussion-paper-use-patient-disease-registries-regulatory-purposes-methodological-operational_en.docx.
[24]	EMA. Discussion paper: Use of patient disease registries for regulatory purposes-methodological and operational considerations. [EB/OL]. [2020-06-20]https://www.ema.europa.eu/en/documents/other/discussion-paper-use-patient-disease-registries-regulatory-purposes-methodological-operational_en.docx.
[25]	SMA NEWS TODAY.Rare Disease Groups Welcome FDA's Embrace of ‘Real World' Data in Clinical Trials[EB/OL]. (2018-03-12)[2020-06-20]. https://smanewstoday.com/2018/03/12/rare-disease-groups-welcome-fdas-embrace-real-world-data-clinical-trials/.
[26]	CHEN W,LIU J P. Definition, design and domestic and foreign progress of registration research[J]. Mod Chin Clin Med(现代中医临床),2014,21(6):23-26.
[27]	THE OHIO STATE UNIVERSITY WEXINER MEDICAL CENTER. NeuroNext Biomarker Study Explores Natural History Of Infantile-Onset SMA [EB/OL]. (2018-01-18) [2020-07-20]. https://wexnermedical.osu.edu/mediaroom/pressreleaselisting/neuronext-biomarker-study-explores-natural-history-of-infantile-onset-sma.
[28]	FRÖBERT O, LAGERQVIST B, OLIVECRONA G K, et al. Thrombus aspiration during ST-segment elevationmyocardial infarction[J]. N Engl J Med,2013,369(17):1587-1597.
[29]	FRÖBERT O, LAGERQVIST B, GUDNASON T, et al. Thrombus aspiration in ST-elevation myocardial infarction in scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationale[J]. Am Heart J, 2010,160(6):1042-1048.
[30]	PRZEPIORKA D, KO C, DEISSEROTH A, et al. FDA approval: blinatumomab [J]. Clin Cancer Res,2015,21(18):4035-4039.
[31]	FDA. Blincyto (blinatumomab) Injection [EB/OL]. (2014-12-03) [2020-07-20]. https://www. accessdata. fda. gov/drugsatfda_docs/nda/2014/125557Orig1s000TOC. cfm.
[32]	EMA. Discussion paper:Use of patient disease registries for regulatory purposes-methodological and operational considerations [EB/OL] (2018-11-05) [2020-07-20]. https://www. ema. europa. eu/en/documents/other/discussion-paper-use-patient-disease-registries-regulatory-purposes-methodological-operational_en. docx.
[33]	BELL J, PARKER K L, SWINFORD R D, et al. Long-term safety of recombinant human growth hormone in children[J]. Clin Endocrinol Metab, 2010,95(1):167-177.
[34]	WENNBERG D E, LUCAS F L, BIRKMEYER J D, et al. Variation in carotid endarterectomy mortality in the medicare population: trial hospitals, volume, and patient characteristics[J]. JAMA, 1998,279(16):1278-1281.
[35]	SEKAR C C, DEMING W E. On a method of estimating birth and death rates and extent of registration[J]. Am Stat Assoc, 1949,44(245):101-115.
[36]	MCGETTIGAN P, ALONSO OLMO C, PLUESCHKE K, et al. Patient registries: an underused resource for medicines evaluation[J]. Drug Saf, 2019, 42(11):1343-1351.
[37]	Late Phase Solutions. Europe is an Independent International Expert in Real World Data and Late Phase Development of Orphan Drugs [EB/OL]. [2020-06-20]. http://latephasesolutions.com/.
[38]	WEINREB N J, KAPLAN P. The history and accomplishments of the ICGG gaucher registry[J]. Am J Hematol,2015,90(suppl 1):S2-S5.
[39]	FDA. Guidance for Industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment [EB/OL]. (2005-05) [2020-06-20]. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf.
[40]	OLMO C A, MCGETTIGAN P, KURZ X. Barriers and opportunities for use of patient registries in medicines regulation[J]. Clin Pharmacol Ther, 2019, 106(1):39-42.
[41]	ZHANG R M, WANG H N, DANG H X, et al. US FDA's new measures for strengthening drug safety administration[J]. Chin Pharm J(中国药学杂志), 2015, 50(10):913-915.
[42]	Food and Drug Administration. Postmarket Requirements (Medical Devices): Post-Approval Studies[EB/OL]. [2020-06-20]. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/PostApprovaStudies/default.htm.
[43]	RESNIC F S, MAJITHIA A, MARINAC-DABIC D, et al. Registry-based prospective, active surveillance of medical-device safety[J]. N Engl J Med, 2017, 376(6):526-535.
[44]	Priyal Patel. Chronic Disease Management through Disease Registries [EB/OL]. (2013-08-14) [2020-06-20]. https://blogs.perficient.com/2013/08/14/chronic-disease-management-through-disease-registries/.
[45]	California Health Care Foundation.Using Computerized Registries in Chronic Disease Care [EB/OL]. (2004-02-19) [2020-06-20]. https://www.chcf.org/publication/using-computerized-registries-in-chronic-disease-care/.
[46]	TAI B, HU L, GHITZA U, et al. Patient registries for substance use disorders[J]. Subst Abuse Rehabil, 2014, 5:81-86.
[47]	Centers for Disease Control and Prevention. National Program of Cancer Registries(NPCR) [EB/OL]. [2020-08-13]. https://www.cdc.gov/cancer/npcr/about.htm.
[48]	RWE Navigator. Patient registries [EB/OL]. [2020-06-20]. https://rwe-navigator.eu/use-real-world-evidence/sources-of-real-world-data/patient-registries/.
[49]	MCGETTIGAN P, ALONSO OLMO C, PLUESCHKE K, et al. Patient registries: an underused resource for medicines evaluation[J]. Drug Saf, 2019,42(11):1343-1351.
[50]	JONKER C J, VAN DEN BERG H M, KWA M S G, et al. Registries supporting new drug applications[J]. Pharmacoepidemiol Drug Saf, 2017, 26(12):1451-1457.